加载中
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
常规交易时段
US$1.28
−US$0.04 · -3.03%
盘中时间采用ET。市场数据可能有所延迟。
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
日内区间
当前US$1.28
52周区间
当前US$1.28
盘中时间采用ET。市场数据可能有所延迟。
NovaBridge Biosciences, a biotechnology firm, primarily focuses on pioneering immuno-oncology treatments for cancer patients within the United States. Its development pipeline features several significant drug candidates: givastomig, a bispecific antibody currently in Phase 1b clinical trials for gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, another bispecific antibody, which is undergoing Phase 1 clinical evaluation for solid tumors. The company maintains a strategic licensing agreement with Ferring International Center SA, encompassing the research, development, manufacturing, import, use, and commercialization rights for FE301, an interleukin-6 inhibitor. Additionally, NovaBridge Biosciences has established collaborations with Bristol Myers Squibb for givastomig's advancement, ABL Bio, Inc. for both givastomig and ragistomig, and TJ Bio for uliledlimab. Founded in 2014 and headquartered in Rockville, Maryland, the entity was formerly named I-Mab, with its transition to NovaBridge Biosciences slated for October 2025.
日内区间
当前US$1.28
52周区间
当前US$1.28
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$8.25
上涨空间 544.53%报告持有此股票敞口的交易所交易基金。
iShares Biotechnology ETFIBB86.15万0.01%108.2亿 USD0.44%US$201.29-1.45%
State Street SPDR Portfolio Emerging Markets ETFSPEM41.18万0.00%175.99亿 USD0.07%US$52.075-0.09%
ALPS Medical Breakthroughs ETFSBIO18.99万0.10%1.87亿 USD0.50%US$52.34-2.80%
State Street SPDR S&P China ETFGXC2.05万0.00%4.53亿 USD0.59%US$85.49-0.23%
ProShares Ultra Nasdaq BiotechnologyBIB5691.840.01%9138.97万 USD1.19%US$105.29-3.22%iShares Biotechnology ETFIBBState Street SPDR Portfolio Emerging Markets ETFSPEMALPS Medical Breakthroughs ETFSBIOState Street SPDR S&P China ETFGXCProShares Ultra Nasdaq BiotechnologyBIBAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
